PFE holds above key SMAs with a 2026 rally, but weak guidance, COVID declines, and patent risks cloud its recovery outlook ...

Pfizer is closing its South San Francisco research site as part of a wider expense reduction effort. Staff at the site are ...

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

Good news has been scarce for this beaten-down drugmaker.

Pfizer (NYSE: PFE) investors got some very bad news when the company was forced to abandon its internally developed GLP-1 ...

Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Click here to find out why PFE stock is ...